Latest Insider Transactions at Igm Biosciences, Inc. (IGMS)
This section provides a real-time view of insider transactions for Igm Biosciences, Inc. (IGMS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IGM Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IGM Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2022
|
George Gauthier Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,096
+23.63%
|
-
|
|
Mar 15
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,319
+26.35%
|
-
|
|
Mar 15
2022
|
Fred Schwarzer CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
23,002
+39.7%
|
-
|
|
Mar 15
2022
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,084
+15.08%
|
-
|
|
Mar 15
2022
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,477
+28.14%
|
-
|
|
Mar 12
2022
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+29.57%
|
-
|
|
Mar 12
2022
|
George Gauthier Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+29.33%
|
-
|
|
Mar 12
2022
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+32.73%
|
-
|
|
Mar 12
2022
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+30.73%
|
-
|
|
Mar 12
2022
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+35.71%
|
-
|
|
Feb 08
2022
|
Michael D Loberg Director |
BUY
Bona fide gift
|
Indirect |
300
+33.33%
|
-
|
|
Feb 08
2022
|
Michael D Loberg Director |
SELL
Bona fide gift
|
Direct |
300
-100.0%
|
-
|
|
Dec 31
2021
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
211
+8.5%
|
-
|
|
Dec 31
2021
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
300
+50.0%
|
-
|
|
Dec 31
2021
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
195
+0.53%
|
-
|
|
Dec 31
2021
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
130
+0.23%
|
-
|
|
Dec 31
2021
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
130
+9.54%
|
-
|
|
Dec 31
2021
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
130
+0.0%
|
-
|
|
Nov 15
2021
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,367
+49.55%
|
$259,175
$25.5 P/Share
|
|
Nov 15
2021
|
George Gauthier Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,367
+43.96%
|
$259,175
$25.5 P/Share
|
|
Nov 15
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,139
+23.64%
|
$253,475
$25.5 P/Share
|
|
Nov 15
2021
|
Fred Schwarzer CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
10,233
+28.18%
|
$255,825
$25.5 P/Share
|
|
Nov 15
2021
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,086
+20.22%
|
$252,150
$25.5 P/Share
|
|
Nov 15
2021
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Nov 02
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,326
-30.25%
|
$67,626
$51.37 P/Share
|
|
Nov 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,174
-21.13%
|
$57,526
$49.78 P/Share
|
|
Nov 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+31.03%
|
$0
$0.93 P/Share
|
|
Oct 06
2021
|
Michael D Loberg Director |
BUY
Bona fide gift
|
Indirect |
300
+50.0%
|
-
|
|
Oct 06
2021
|
Michael D Loberg Director |
SELL
Bona fide gift
|
Direct |
300
-100.0%
|
-
|
|
Oct 05
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,242
-28.89%
|
$79,488
$64.1 P/Share
|
|
Oct 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,258
-22.64%
|
$81,770
$65.91 P/Share
|
|
Oct 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+31.03%
|
$0
$0.93 P/Share
|
|
Sep 30
2021
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
130
+10.55%
|
-
|
|
Sep 30
2021
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
211
+9.29%
|
-
|
|
Sep 30
2021
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
300
+50.0%
|
-
|
|
Sep 30
2021
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
195
+0.53%
|
-
|
|
Sep 30
2021
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
130
+0.23%
|
-
|
|
Sep 30
2021
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
130
+0.0%
|
-
|
|
Sep 03
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,244
-28.92%
|
$87,080
$70.69 P/Share
|
|
Sep 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,256
-22.6%
|
$89,176
$71.79 P/Share
|
|
Sep 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+31.03%
|
$0
$0.93 P/Share
|
|
Aug 09
2021
|
Julie Hambleton |
SELL
Open market or private sale
|
Direct |
1,000
-33.33%
|
$80,000
$80.0 P/Share
|
|
Aug 04
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,242
-28.89%
|
$83,214
$67.0 P/Share
|
|
Aug 02
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,258
-22.64%
|
$83,028
$66.96 P/Share
|
|
Aug 02
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+31.03%
|
$0
$0.93 P/Share
|
|
Jul 08
2021
|
Michael D Loberg Director |
BUY
Bona fide gift
|
Indirect |
300
+2.26%
|
-
|
|
Jul 08
2021
|
Michael D Loberg Director |
SELL
Bona fide gift
|
Direct |
300
-100.0%
|
-
|
|
Jul 06
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
943
-0.8%
|
$77,326
$82.75 P/Share
|
|
Jul 06
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,247
-28.97%
|
$102,254
$82.5 P/Share
|
|
Jul 01
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
957
-0.81%
|
$85,173
$89.43 P/Share
|